NO20025138L - Daglig behandling av ereksjons-feilfunksjon ved anvendelse av en PDE5 inhibitor - Google Patents

Daglig behandling av ereksjons-feilfunksjon ved anvendelse av en PDE5 inhibitor

Info

Publication number
NO20025138L
NO20025138L NO20025138A NO20025138A NO20025138L NO 20025138 L NO20025138 L NO 20025138L NO 20025138 A NO20025138 A NO 20025138A NO 20025138 A NO20025138 A NO 20025138A NO 20025138 L NO20025138 L NO 20025138L
Authority
NO
Norway
Prior art keywords
erectile dysfunction
daily treatment
pde5 inhibitor
pde5
inhibitor
Prior art date
Application number
NO20025138A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025138D0 (no
Inventor
John Steven Whitaker
Inigo Saenz De Tejada
Kenneth Michael Ferguson
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of NO20025138D0 publication Critical patent/NO20025138D0/no
Publication of NO20025138L publication Critical patent/NO20025138L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20025138A 2000-04-26 2002-10-25 Daglig behandling av ereksjons-feilfunksjon ved anvendelse av en PDE5 inhibitor NO20025138L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/558,911 US6451807B1 (en) 1999-04-30 2000-04-26 Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
PCT/US2001/012512 WO2001080860A2 (fr) 2000-04-26 2001-04-13 Traitement quotidien de la dyserection utilisant un inhibiteur de pde5

Publications (2)

Publication Number Publication Date
NO20025138D0 NO20025138D0 (no) 2002-10-25
NO20025138L true NO20025138L (no) 2002-12-16

Family

ID=24231497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025138A NO20025138L (no) 2000-04-26 2002-10-25 Daglig behandling av ereksjons-feilfunksjon ved anvendelse av en PDE5 inhibitor

Country Status (20)

Country Link
US (2) US6451807B1 (fr)
EP (1) EP1276481A2 (fr)
JP (1) JP2003531174A (fr)
KR (1) KR20030007551A (fr)
CN (1) CN1446091A (fr)
AU (1) AU2001253612A1 (fr)
BR (1) BR0110373A (fr)
CA (1) CA2407519A1 (fr)
CZ (1) CZ20023577A3 (fr)
EA (1) EA200201011A1 (fr)
HR (1) HRP20020827A2 (fr)
HU (1) HUP0300477A3 (fr)
IL (1) IL152227A0 (fr)
MX (1) MXPA02010539A (fr)
NO (1) NO20025138L (fr)
NZ (1) NZ521869A (fr)
PL (1) PL360186A1 (fr)
SK (1) SK15392002A3 (fr)
WO (1) WO2001080860A2 (fr)
ZA (1) ZA200208776B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
US6943166B1 (en) * 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
HUP0001632A3 (en) * 1999-04-30 2001-12-28 Lilly Icos Llc Wilmington Pharmaceutical compositions comprising selective phosphodiestherase inhibitors
EP1365806A2 (fr) * 2000-04-19 2003-12-03 Johns Hopkins University Utilzation d'activators de no pour le traitement et la prevention des troubles gastrointestinaux
US8133903B2 (en) * 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
AU2005277384B2 (en) * 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7265248B1 (en) 2005-04-29 2007-09-04 Technology Innovations, Llc Compositions and methods for the treatment of malaria
WO2007100387A2 (fr) * 2005-11-03 2007-09-07 Dr. Reddy's Laboratories Ltd. Procédé de préparation de tadalafil
EP2705753A1 (fr) 2006-08-24 2014-03-12 Surface Logix, Inc. Dérivés de 2-Phenyl-imidazolotriazinone comme inhibiteurs de la PDE5
TWI462923B (zh) * 2010-10-18 2014-12-01 Univ Kaohsiung Medical Ｋｍｕｐ－３之心肌梗塞疾患用途
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil
JP6578046B1 (ja) * 2018-08-23 2019-09-18 Ｔｏｗａ Ｃｏｒｐｏｒａｔｉｏｎ 株式会社 Ｐｄｅ５阻害用医薬組成物及びｐｄｅ５阻害用食品組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931445A (en) 1988-10-06 1990-06-05 Irwin Goldstein Agents for treatment of male impotence
NZ234186A (en) 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
EP1038963B1 (fr) 1993-05-27 2009-08-05 Board Of Regents Of The University Of Washington Phosphodiésterase de fixation du monophosphate de guanosine cyclique et avec specificité pour celui-ci et procédé d'obtention
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
DE69711882T2 (de) 1996-05-10 2002-10-31 Icos Corp Carbolinderivate
WO2000015639A1 (fr) 1998-09-16 2000-03-23 Icos Corporation Derives de carboline en tant qu'inhibiteurs de la gmp cyclique phosphodiesterase

Also Published As

Publication number Publication date
KR20030007551A (ko) 2003-01-23
US6451807B1 (en) 2002-09-17
EA200201011A1 (ru) 2003-06-26
NZ521869A (en) 2004-10-29
US20030100478A1 (en) 2003-05-29
NO20025138D0 (no) 2002-10-25
PL360186A1 (en) 2004-09-06
WO2001080860A2 (fr) 2001-11-01
JP2003531174A (ja) 2003-10-21
CA2407519A1 (fr) 2001-11-01
HUP0300477A2 (hu) 2003-06-28
HRP20020827A2 (en) 2004-12-31
MXPA02010539A (es) 2003-05-14
HUP0300477A3 (en) 2004-10-28
IL152227A0 (en) 2003-05-29
ZA200208776B (en) 2003-06-03
BR0110373A (pt) 2003-02-18
WO2001080860A3 (fr) 2002-06-06
AU2001253612A1 (en) 2001-11-07
CZ20023577A3 (cs) 2003-06-18
SK15392002A3 (sk) 2003-03-04
EP1276481A2 (fr) 2003-01-22
CN1446091A (zh) 2003-10-01

Similar Documents

Publication Publication Date Title
IL153492A0 (en) Treatment of male sexual dysfunction
GB0025782D0 (en) Use of inhibitors
NO20025138D0 (no) Daglig behandling av ereksjons-feilfunksjon ved anvendelse av en PDE5 inhibitor
SG94727A1 (en) Treatment of a metal nitride/metal stack
EP1385434A4 (fr) Traitement du prolapsus vaginal
HK1122326A1 (en) Use of moo3 corrosion inhibitor moo3
AU8969601A (en) New use of lipase inhibitors
HK1055087A1 (en) Use of cox-2 inhibitors as immunostimulants in thetreatment of hiv or aids
EP1337255A4 (fr) Utilisation d'inhibiteurs p38 pour le traitement de toux inflammatoire
EP1248593A4 (fr) Traitement de l'immunosuppression provoquee par les uv
NO20030978D0 (no) Behandling av diuresedysfunksjon
AU5000001A (en) Treatment of vitiligo
EP1309552A4 (fr) Composes et inhibiteurs de phospholipases
AU2002246924A8 (en) Treatment of erectile dysfunction with rho-kinase inhibitors
NO20041938L (no) Anvendelse av fosfodiesterase IV-inhibitorer
IL155775A0 (en) Treatment of male sexual dysfunction
PL362980A1 (en) Treatment of sexual dysfunction
GB0029903D0 (en) Use of anti-muscarinic agents
GB0029468D0 (en) Use of disazo compounds
PT1273556E (pt) Estacao de tratamento simbiotico de aguas residuais.
AU2001258598A1 (en) Use of metal compounds to treat gastrointestinal infections
AU1212002A (en) Use of lipase inhibitors
AU2003287388A8 (en) Inhibition of hiv-1 replication
EP1303281A4 (fr) Methodes de traitement
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application